Conray 400

arthrography, peripheral arteriography, intravenous excretory urography + 11 more
Treatment
13 FDA approvals
20 Active Studies for Conray 400

What is Conray 400

Iothalamic acidThe Generic name of this drug
Treatment SummaryIothalamic acid is a medication containing iodine that can be used to make medical images clearer and easier to read.
Glofil-125is the brand name
Conray 400 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Glofil-125
Iothalamic acid
1983
7

Approved as Treatment by the FDA

Iothalamic acid, otherwise called Glofil-125, is approved by the FDA for 13 uses which include Kidney Diseases and peripheral arteriography .
Kidney Diseases
peripheral arteriography
Bone structure of cranium
computerized tomography
venography
Chronic Kidney Disease (CKD)
Glomerular Filtration Rate (GFR)
arthrography
cerebral angiography
Endoscopic Retrograde Cholangiopancreatography
Cholangiography
angiogram
intravenous excretory urography

When to interrupt dosage

The proposed dosage of Conray 400 is based on the determined condition, including cerebral angiography, venography and cystourethrography. The quantity of dosage is contingent upon the technique of delivery (e.g. Solution or Intra-arterial; Intravenous) specified in the table underneath.
Condition
Dosage
Administration
arthrography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
peripheral arteriography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
intravenous excretory urography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
venography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
computerized tomography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
cerebral angiography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
retrograde cystography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
angiogram
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Bone structure of cranium
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Chronic Kidney Disease (CKD)
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Endoscopic Retrograde Cholangiopancreatography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Glomerular Filtration Rate (GFR)
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
cystourethrography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous
Cholangiography
, 0.275 mCi/mL, 54.3 %, 66.8 %, 172.0 mg/mL, 300.0 mg/mL, 600.0 mg/mL, 430.0 mg/mL, 668.0 mg/mL, 1.0 mg, 780.0 mg/mL, 260.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intravascular, Solution, Solution - Intravascular, Urethral, Solution - Urethral, Liquid - Urethral, Liquid, Intra-arterial; Intravenous, Solution - Intra-arterial; Intravenous, Solution - Intravenous, Ureteral, Injection, Injection - Ureteral, Injection - Intravascular, Injection - Intravenous

Warnings

Conray 400 has seven contraindications, and it should not be used when enduring the conditions indicated in the following table.Conray 400 Contraindications
Condition
Risk Level
Notes
myelography
Do Not Combine
Pancreatitis
Do Not Combine
Prothrombin time prolongation
Do Not Combine
Endoscopy (procedure)
Do Not Combine
infection near the joint
Do Not Combine
Blood Coagulation Disorders
Do Not Combine
Cholangitis
Do Not Combine
There are 20 known major drug interactions with Conray 400.
Common Conray 400 Drug Interactions
Drug Name
Risk Level
Description
Acrivastine
Minor
Iothalamic acid may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Iothalamic acid may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Almasilate
Minor
Iothalamic acid may decrease the excretion rate of Almasilate which could result in a higher serum level.
Antihemophilic factor (recombinant), PEGylated
Minor
Iothalamic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antithrombin III human
Minor
Iothalamic acid may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.

Conray 400 Novel Uses: Which Conditions Have a Clinical Trial Featuring Conray 400?

236 active trials are being conducted to explore the utility of Conray 400 for venography, Glomerular Filtration Rate (GFR) estimation and angiogram.
Condition
Clinical Trials
Trial Phases
cystourethrography
0 Actively Recruiting
peripheral arteriography
0 Actively Recruiting
Endoscopic Retrograde Cholangiopancreatography
0 Actively Recruiting
cerebral angiography
0 Actively Recruiting
Bone structure of cranium
0 Actively Recruiting
Chronic Kidney Disease (CKD)
28 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 1, Phase 4
intravenous excretory urography
0 Actively Recruiting
angiogram
0 Actively Recruiting
Glomerular Filtration Rate (GFR)
0 Actively Recruiting
Cholangiography
0 Actively Recruiting
venography
0 Actively Recruiting
computerized tomography
1 Actively Recruiting
Phase 2
retrograde cystography
0 Actively Recruiting
arthrography
0 Actively Recruiting

Patient Q&A Section about conray 400

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Conray used for?

"Conray is a contrast agent used in diagnostic procedures such as excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, and cranial computerized angiotomography. It is also used to enhance computed tomographic brain images."

Answered by AI

What is Conray 43 used for?

"Conray 43 is a diagnostic tool that uses radiopaque medium to create images of the lower extremities, urinary tract, brain, and arteries."

Answered by AI

What is Vasodilan used for?

"This medication is typically used in conjunction with other treatments for blood vessel diseases such as arteriosclerosis obliterans, Raynaud's disease, Buerger's disease, and cerebrovascular insufficiency."

Answered by AI

How is Conray administered?

"This medication may be given in two ways- all at once (bolus injection), or over a period of time (rapid infusion). The usual dose for adults and children is 0.5-1 mL per kilogram of body weight. For the bolus injection, the medication should be injected at a rate of 2 mL per second, and scanning should begin immediately after administration. This dose may be given more than once if necessary."

Answered by AI

Clinical Trials for Conray 400

Have you considered Conray 400 clinical trials? We made a collection of clinical trials featuring Conray 400, we think they might fit your search criteria.Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Inspire HER for Cardiovascular Disease

30 - 79
Female
Birmingham, AL
Poor heart health puts Black women at risk for a shorter life with more illness than people of any other non-indigenous racial group. We will refine and conduct a randomized, wait-list controlled trial of Inspire HER (a heart health lifestyle intervention for Black women that provides health education, physical activity, and social resources). We will also compare Inspire HER and Black Impact (a heart health intervention for Black men) data to study how women and men respond differently to stress. This trial aligns with American Heart Association's pledge to address heart health equity through new interventions that consider the person and the circumstances with which they live.
Waitlist Available
Has No Placebo
University of Alabama at BirminghamTimiya S Nolan, PhD
Image of South Florida Research Institute in Lauderdale Lakes, United States.

Mezagitamab for Berger's Disease

18+
All Sexes
Lauderdale Lakes, FL
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo. Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed in 1 of the 2 treatment groups by chance (either mezagitamab or placebo) at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. The participants will receive either mezagitamab or placebo for almost half a year in two 1-year cycles. They will be observed for another half year in each 1-year cycle and will have check-ups about every month during this time. In the open-label group, a small number of participants who have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab. During the study, participants will visit their study clinic several times.
Phase 3
Recruiting
South Florida Research Institute (+17 Sites)Study DirectorTakeda
Have you considered Conray 400 clinical trials? We made a collection of clinical trials featuring Conray 400, we think they might fit your search criteria.Go to Trials
Image of University of California, San Francisco School of Medicine in San Francisco, United States.

Valganciclovir for Cytomegalovirus Infection

18+
All Sexes
San Francisco, CA
This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in an open label design, either AP with valganciclovir 900 mg orally once daily or letermovir 480 mg orally once daily \[both dose adjusted per Food and Drug Administration (FDA) label\] for 200 days post-transplant), or PET (central lab weekly plasma polymerase chain reaction (PCR) monitoring for CMV deoxyribonucleic acidemia (DNAemia)) for 100 days post-transplant, with oral valganciclovir 900mg orally twice daily (or renally dosed per FDA label) at onset of CMV DNAemia at any level and continued until plasma CMV DNAemia is negative or below the level of quantitation in two consecutive weekly plasma samples. Study participants will be followed for pre-specified outcomes (clinical, laboratory, immunologic, safety) until withdrawal, death, or study closure, up to a maximum of 5.5 years post-transplant. Approximately 360 participants (180 participants in each group) will be randomized into the study. Estimated Time to Complete Enrollment: 4 years
Phase 3
Recruiting
University of California, San Francisco School of Medicine (+4 Sites)Abhijit P. Limaye, MD
Image of Emory University Hospital Midtown in Atlanta, United States.

Kidney Health Coaching for Kidney Disease

18+
All Sexes
Atlanta, GA
Through the use of community-engaged processes and an anti-racism approach, this project seeks to develop and implement clinical decision support (CDS) and a kidney health coaching (KHC) intervention. The CDS seeks to streamline workflows to effectively screen, identify, and link to care for those patients with advanced chronic kidney disease (CKD). The overall project goals are to 1.) Design and conduct community-engaged clinical trials to test new interventions that dismantle the effects of structural racism that contribute to kidney health disparities. 2.) Foster research collaborations between investigators, people living with kidney disease, community-based organizations, and other key stakeholders. Researchers aim to assess whether the KHC intervention is effective at delaying the transition to kidney replacement therapy (KRT) and central venous catheter use or death.
Waitlist Available
Has No Placebo
Emory University Hospital MidtownKimberly R Jacob Arriola, PhD, MPH
Image of London Health Sciences Centre in London, Canada.

Expanded Hemodialysis for Chronic Kidney Disease

18+
All Sexes
London, Canada
The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is: 1\) Does expanded hemodialysis reduce the risk of death from any cause? Researchers will compare expanded hemodialysis to conventional hemodialysis (the treatment currently used for the majority of patients receiving hemodialysis) to see if expanded hemodialysis works to improve patient outcomes. Participants will continue to receive their regularly scheduled hemodialysis treatments using either a super high-flux/expanded dialysis filter or a high-flux/conventional dialysis filter. All other aspects of treatments remain the same. No additional tests or visits are required. Data will be obtained using administrative healthcare databases and medical record review (at a subset of participating locations).
Recruiting
Has No Placebo
London Health Sciences CentrePavel S Roshanov, MD MSc FRCPCICES
Have you considered Conray 400 clinical trials? We made a collection of clinical trials featuring Conray 400, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security